Clinical trial
Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer…
NCT00259129 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00259129 |
|---|---|
| Title | Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients |
| Official title | Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms |
| Intervention type | Drug |
| Interventions | Sorafenib (Nexavar, BAY43-9006) |
| Enrollment | 53 |
| Start date | Aug 1, 2005 |
| Primary completion | Feb 1, 2007 |
| Completion | Mar 1, 2008 |
| First posted | Nov 29, 2005 |
| Last update posted | Nov 13, 2014 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: